IBD

Stocks_N_Bondage

Huh? I've looked at her portfolio. Nothing special, so who cares? It's a basket of the most milquetoast growth stocks that anyone with an IBD subscription probably owns. Whatever.

Jazzlike-Lion2969

So, we are talking about the last few weeks. Not the whole year. Just current market 3 weeks. IBD has been pointing out the negative breath in the big picture lately. I’ve seen it in my account. Nothing to lie about? I’m down 14% in 3 weeks.not feelings or lies? I’ve had a great 3 years. We are due for a pullback. I’ve been trading since 1994. Been through a few cycles. I traded during dotcom. And Ai feels that way.  I don’t know your history. 

Icy-Sprinkles-6964

You can say that, but added few more details. Lol, Just now Luke-Grice-Lowe (Director of IBD at Multisensor AI) accepted my LinkedIn connection request. Do you guys want me to ask some insider info🤣? https://preview.redd.it/niek52fiosxf1.jpeg?width=1320&format=pjpg&auto=webp&s=29006441213a95e6b85c31ca007182422d034e65

D_Pablo67

I am a member of the American Association of Individual Investors, which has a great investor education website, including model portfolios by investing style. Any trading platform should give you access to research and allow you to set up screens. I read research reports from Bank of America, CFRA and Morningstar. I read Yahoo Finance, Bloomberg, Zack’s and IBD.

BLISSING_ALWAYS

“My” advice is the advice of William O’Neill, founder of Investors Business Daily! investors . com   The 5% rule!!!  If you don’t know who William O’Neill is, check out IBD or his books. William ONeil remains a giant in his field.  Lucent was an awesome company for years and years, unlike Enron. Their R&D made Lucent into a TRUE giant. A change in leadership killed them.  I know people who owned Lucent for years as it rose and rose, but then they also continued to hold - and held on til the bitter end, hoping it would recover its former glory.  “Countless studies” are for generic average joes who don’t want to self-educate, paper trade, and pay attention to the market, or who don’t have the temperament or the time for it. Education is key! And it can be time consuming if you don’t have a mentor who has stayed safe and profitable over crashes as well as booms, plural, and over the decades.  Another market truth is that you have to trade your personality. You can’t throw your money into a boglehead investment fund and ignore it for years if you’re an extremely ambitious &/or extremely (ironically) risk-averse, nervous day trader - nor vice versa. Otherwise you’re endlessly fighting yourself; you end up fighting your own nature. Those who say you can’t time the markets are just plain wrong. I used to hang out with traders. Charlie Manning posted trades publicly on the internet every day for a year or something and only broke his winning streak a day or two before his wedding day, lol - nuptial jitters!  Know thy self! Cheers to all! Love to all! ❤️🙏❤️

Stocks_N_Bondage

I mostly use ThinkorSwim. I also use ZenBot, and I use MarketSurge, IBD, and some AI platforms.

ViProCon

Just seeing this now, with 221 comments already posted so I'm sure there's lots said. But my 2 cents is that I bought shares of TMQ,.....JUST as it was at its height somewhere in the 10.50-ish range. Now a week later the damn thing is like 50% declined. Un-f-ing real. I didn't think to put stops, figured this would likely be a keeper. It still will be once the overall metals market recovers, but it is abosultey a sh\*t show for metals right now. No clue what USAR was doing the other day but it went pretty high for a bit, yesterday. Also, the AI bubble has popped too it feels like. I have like . Maybe a minor thing but I have about 15 positions in various stocks that are not NVDA and the usual suspects. I'm into NBIS, IREN, MP, APLD, BITF, among others. Every single one of them is 5-20% down since I bought. There's nothing about the AI market right now that's any bit good IMHO. I imagine this will reverse, but fuzz. Also I'm into quantum a bit - every single one of those positions is way down. IONQ for example. Very peculiar the Seeking Alpha, Benzinga, IBD etc. are not saying much about this.

BLISSING_ALWAYS

Learn all about automated stop-loss orders! How to use them optimally is a study in itself - a very profitable one!!   Learn how to place trailing stop orders. Refuse to lose any more than 5% MAX - William O’Neil’s classic IBD advice - and Chris Manning’s, too, if I recall correctly.  Maybe set the stop-loss at less than 5% if it’s a high price-per-share of stock. Don’t place the stop at round numbers. Don’t worry about market makers manipulating the price moves to shake you out of your trade on purpose. Your live-to-trade-another-day safety is what’s most important! But don’t be oblivious to market makers shenanigans, either.  There’s so much good stuff to learn to keep your cash safe.  Btw, automated stop-losses apparently work best in the futures markets…which is super-liquid.  A profitable trader I met told me he considered his entire job to be “risk management”!! P.S. Probably bad advice, here, lol. Ignore me!😂😃🤣😅

SoCal_IrieGuy

Maybe Im old school but I like to read IBD of course now I do it on the app.

Stocks_N_Bondage

LOL. Their gross margins were NEGATIVE previous quarter, this quarter an abysmal 11%, but more importantly, NET margins are decidedly negative: pre-tax margin is a -41%. That means they are losing money by the bucketfulls. The alpha is -0.7, the book value is 9 cents, the cash flow is negative and IBD rates them as a 1, the literal lowest possible score. Sales fell 20%, and have been plummeting every quarter. Debt to capital is 214. **OMG.** Don't tell me "how it works" Poindexter. The company is trash.

gamjatang111

I entered the workforce in 2012 on the IBD team at GS in Canada. It was absolutely the best of times, deals flying left and right.

SensitiveVisit2087

$APP The SEC has not accused AppLovin of committing any violations, the report said. AppLovin, which helps mobile app developers find users and sell advertising in their apps, has seen its shares surge this year on booming sales and earnings. AppLovin stock hit a record high of 745.61 on Sept. 29. However, on the stock market today, AppLovin tumbled 14% to close at 587. Earlier in the day, Wedbush Securities analyst Alicia Reese reiterated her outperform rating on AppLovin stock and raised her price target to 745 from 725. Reese expressed confidence that AppLovin can continue its heady growth as it rolls out new services for advertisers and app developers. AppLovin stock is on four IBD lists: IBD 50, Big Cap 20, Leaderboard and Tech Leaders. Follow Patrick Seitz on X at @IBD_PSeitz for more stories on consumer technology, software and

gmnotyet

The fuck happened to Dutch Brothers? They were IBD's Growth Stock of the Day a few weeks ago.

K-Uno

IBD? Whats that?

Grouchy-Dot2891

Man I saw this stock as #1 on IBD and I'm like IREN huh, $26. Not bad. Now it's double like a month later.

TheInkDon1

Well, you can feel the way you feel, but I don't think you're looking at it quite correctly. I don't know how you invest, but do you buy stocks? I'll assume that you do, or have. Call options are just a cheaper way to 'own' shares. Not OWN, but rent, for the cost of the theta/extrinsic value in the Call you buy. And because the Call is so much cheaper than shares, you get a great deal of leverage. And what's the downside? The loss of the whole cost of the Call. But you won't let it come to that, because you'll monitor every week and sell the Call at half, or at some point you set for yourself. Do you use a stop-loss for shares? If you're familiar with that concept, you can translate that number, the dollar loss you'd be willing to take on shares, and close the Call if it dips that much. And the gains aren't linear: they're multiplied by the leverage of the Call at any point in time: Spot divided by Call price, then multiplied by Delta. For a **GLD** Call at 360DTE and 80-delta, that's a **leverage factor of 6.5.** *It's worth taking* ***some*** *risk for that kind of multiplier.* And when to get out after making a profit is easy: whenever you want to. At whatever profit percentage you set for yourself. But as long as the stock is going up, and therefore the value of the Call is increasing, why get out? I hold them till the stock's price starts to roll over. With ETFs that's easy to see on a weekly or monthly time scale, and ETFs don't drop quickly like individual stocks do. And if you think the price of a 1y Call is too high, okay: come in to 100-120 days. Based on experience I'd made a rule for myself to stop selling inside 3 months. Then someone here mentioned the 100-120DTE thing. After doing some research, and because it fit my own experience, I've adopted that for some of my trades. So then, for GLD the price of the Call comes down from $42.68 at 360DTE to just 27.90 at 115DTE. And that's just 8% of GLD's $346 current price. Are you familiar with Investor's Business Daily? They recommend selling a stock if it drops 8% from where you bought it. So look at that: buying that 115DTE Call for just 8% of GLD's price is a built-in stop loss. If GLD drops enough to make the Call worthless, you've only lost 8%, which is what IBD recommends as a stop-loss point. There's a lot to recommend deep-ish ITM Calls a few months out or more.

nonchalant450

I have been a member of MPA for multiple years, and his MPA membership is way toooooo expensive for what it is in my opinion. And there is a wide spread expressions by the members and the previous members of MPA saying that he is front running, selling into strength of his picks when the stock prices spike after his and then his members' buys shortly after the platform's recommendations. I think many believe that this happens because of the platform's liking for small and mid cap stocks which have smaller floats. They really should institute a "minimum wait time" requirement like the IBD's 30 minute wait time requirement before the owner and the employees' of MPA can buy the stocks that they had just recommended. But perhaps more importantly, their performance in the last couple of years or so has been dismal: their Select Portfolio is down by a high single digit percentage since 4/24 while the indices produced huge returns. Why pay soooo much money, work so hard going in and out of stocks, lose sleep, and lose money when you can sit, and do nothing indexing????? Trying to climb out of a hole by following their picks also fighting the reverse compounding effect including on the many thousands of dollars paid in fees paid to MPA would be a very tall order in my opinion.

PixiePower65

I have really appreciated IBD It’s a real time class. Morning and 4:00. They break down market individual stocks. Access to their resources. They run a portfolio- send you noticed on when they enter /exit/ trim Both positional and their specialty Swing Trading . Both growth strategies and conservative methods. Can find them on you tube to start. Yep it’s their pitch. It’s free but you still learn. Then they have products. Has seriously paid for itself.

Walking72

IBD:  Nvidia's Moat Not At Risk After Broadcom News

songbird516

Yes, we have a house/mortgage but no other debt. We do pay a little extra on the mortgage, but current finances didn't allow for much savings, and we don't want to take this windfall and put it all on the mortgage. I appreciate your time to write that out, and will add IBD to my watch list.

twi1i96tr

Hello... My first question is do you have/own a principle residence? If not... buy a house. Whether you own or are renting you are paying a mortgage. When you rent you pay the landlord's mortgage. When you own you pay your own mortgage. Second question is "If you have a principle residence"... is the mortgage paid off? If you have a mortgage pay it off before you do anything else. Once you own a home and are mortgage free your financial life will change forever. If that's not for you look at buying good dividend paying stocks and maybe a DRIPS program rather than spending the dividends. Diversify to AT LEAST 4 stocks but make sure they are stable companies that pay dividends. And don't make the mistake of just looking at the dividends. Companies that pay too high a dividend are mostly risky. Look at the long term financial stability of the company first. If you want to manage your own money I would highly recommend you watch IBD (Investors Business Daily) on Youtube and learn about their CANSLIM strategy. Also take a look at what Warren Buffet buys. It works for him. Best of Luck.. Twilighter.

Straight-Annual8687

RIGL was added to the IBD50 list EOD yesterday. Long term bullish event. Money should move to small cap after nvda results. Today, low volume, low float, company is very solid with profits, cash, pipeline, partners, and trading with a low PE that can triple or more just to get with sector average. RIGL will easily survive on its own, but more likely a $2B-$3B acquisition target which would blow the stock out to about $150. I'm holding long on this one - it'll dip and bob and weave but the finish line is going to be fantastic

cbusoh66

GOOG is going to rocket on the ruling because all indications point to a simple slap on the wrist. https://www.investors.com/news/technology/google-stock-wall-street-awaits-judges-ruling-on-remedies-in-search-antitrust-case/ >"There's a sizable menu of options for him to choose from," William Kovacic, a professor at George Washington University Law School, told IBD. Kovacic served as Federal Trade Commission chairman in the George W. Bush administration. >"I suspect that he will be inclined to do more than simply issue an injunction that says Google must discontinue harmful behavior," Kovacic added. "**In his original decision Judge Mehta said Google has done some valuable things for the economy and for individual consumers. So I think he's wary of a form of intervention that would disable Google from being an effective competitive force in the future**."

MyndexResearch

TGT is at $104.9, definitely room to go down. Its P/E is 13, but its 5 year P/E low is 10, so it could easily drop 30% and still be within its recent PE range. And don't forget, earnings could miraculously go up, but guidance goes down, so the stock sinks yet maintains P/E... P/E is a terrible guide! ## *"Crazy low"* means something is *"crazy wrong"*. TGT's sales are crap, earnings are crap, RS is crap, negative growth, A/D is crap, and the IBD comp rating is a crap-tastic 10. Funds own 45%, so there's room for funds to dump shares straight into the abyss. If it doesn't hold above the support at 88, next down is about 71-ish. It's barely above the April lows. But this is not a full opinion, I need to see how the week plays out. Rn, its chart looks weird. But at the moment, I'm thinking puts.

1UpUrBum

IBD Investors Business Daily

roarroar6767

“How to make money in stocks” by William O’Neill. Great book. I got the third edition. Not sure if all copies have this but there is a huge section in this book detailing the information IBD was providing at the time.

roarroar6767

“How to make money on stocks” by William O’Neill. Great book. I got the third edition. Not sure if all copies have this but there is a huge section in this book detailing the information IBD was providing at the time.

Chrishall86432

Started in 1984. My Dad did quite well, doing all of the things mentioned but IBD was one of his favorites. Well into the 2010s he would still make copies of articles in the WSJ at the library and mail them to us.

Simon_Inaki

# Equíllium special situation trade (ultra, ultra risky). So this company located in an ultra high COL city (La Jolla, CA which btw has a fkn siiiiick breakfast place called Richard Walker's pancake house) has been a stock I have made money on when a bunch of fomo surrounded the stock for vitiligo which is blotchy skin. That flopped. The stock used to be continuously funded by a bunch of funds and big investors, and interest gradually faded. Sometime earlier this year one of those investors, gave the company more money and also effectively reverse merged Aríagen, a private company, into EǬ. Let's treat the company going forward as NewQ for now. In this transaction NewQ gained some cash, and the rights to EǬ504, an AhR modulator. It's thought that AhR modulators can control inflammatory response, but the science is still being iterated on. I am not a scientist. EǬ, if we are to believe their 5-02 deck suggests that with modifications these molecules can target various parts of the body **without** systemic effects (important!). Similar to a guided munition vs a blanket attack (not good!). recently the stock experienced some surges in volume potentially from people buying up the stock as Abi vax got picked up for 4.6Bn Euros. Why? Because Abi vax's Obefazimod enhances the expression of microRNA-124. It is generally well understood that MiR124 and AHR play very important roles in the inflammatory response. Therefore, it could be the case that EǬ504 if funded, becomes a candidate for alleviating inflammatory bowel diseases such as ulcerative colitis. Keep in mind the company will owe the fund $55Mn if the drug is *successful enough.* Additionally, this fund has significant control over NewQ (risk!) Last Monday the company put out a very odd PR: they are buying crypto with their reserves and they moved their ATM with LifeSci (this company does a lot of biotech fundraising and IB). The stock's momentum died and there's been 2-3 days of 1.5-2mm volume and the last most recent day with <600k volume. The company is nearly broke, and you never want to buy into an ATM. Because a company hitting an ATM at low prices tells you the company is desperate and couldn't gather investors. Earnings are on the 13th. I believe that the company could very well reveal a registered offering and reorganization. It's the summer, people go on vacation all the time. Key persons could come back from a bender in Ibiza and have a chat with qualified investors and raise $50mn. If this happens the new investors of NewQ will be locked up and you could be the shareholder of NewQ with more money and more shares issued, but the picture will be the same as now float wise. + the company will initiate development of the drug. Bull case – Company completes offering and reorganization, secures sufficient funding to advance EǬ504 into development, attracts investor interest from the AhR angle for IBD / Autoimmune and skin diseases. Market cap could trend toward $300–400 million over time if progress is made. Bear case – No offering is completed instead there is ongoing ATM usage at low prices suppresses share price, potentially keeping it under $0.50 for an extended period along with free float rocketing. But the company starts development anyway. Super-bear case – Company fails to secure funding or delays development significantly, leading to insolvency or bankruptcy. Long and underwater btw.

Capernaum68

And all of your research came from the physical paper pages of IBD

West-Significance-40

You should never wait for a stock to drop to a lower price before you buy. Once it starts to drop when will it stop? Not at your purchase price. Read IBD and buy when the stock moves up on increasing volume. Waiting for a better price will keep you out of the market at a time when you most need to be in it.

Rav_3d

CANSLIM is still a winning strategy. It really comes down to identifying leading companies in leading sectors and buying their stocks at low risk entries, then letting them work for you while you sit on your hands. I use IBD ratings to gauge the fundamentals and relative strength of stocks. It's good enough for me, I don't care to do a deep dive into company fundamentals. If institutions are supporting the stock, that is what is most important. By far, the most important aspect of investing in individual stocks is managing risk. Cutting losses quickly when the entry does not work out as hoped is crucial. Even the best stocks will have deep pullbacks when the inevitable market pullbacks and corrections come. Staying solvent and keeping as much capital for the best opportunities is key to long-term success.

narayan77

Giiant pharma are not listed. Their activities are supported by supported by a $500,000 grant received from the US Crohn’s and Colitis Foundation, through its IBD Ventures program. More on funding: In **May 2024**, the company raised approximately **$4 million** via a private placement led by Ladenburg Thalmann, explicitly earmarked for PALI‑2108 development and working capital in **December 2024**, they completed an **underwritten public offering**, securing about **$5 million** from new common shares and warrants—proceeds earmarked for clinical trials, R&D, and working capital Through their Giiant Pharma co‑development, Palisade received **CAD$1.39 million** from Canada’s SR&ED tax credit (early 2025), reimbursing preclinical development expenses for PALI‑2108 This stock will most likely increase the release of more data. They might need to dilute, my hunch is they could get non-dilutive grants. I might be useful to listen on their earnings call (if they have one).

Jaquing-Porneaux

Executive Summary Palisade Bio is advancing PALI-2108, a novel, orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug for the treatment of ulcerative colitis (UC). The company has recently reported positive topline results from its Phase 1a clinical trial and is proceeding with a Phase 1b study. Financially, the company is in a precarious position, with a limited cash runway that will necessitate additional funding in the near future. The management team, however, brings relevant experience in drug development and financial management. The competitive landscape for IBD is crowded, but PALI-2108's targeted delivery mechanism could offer a key differentiator. The success of Palisade Bio hinges on the continued clinical advancement of PALI-2108 and the company's ability to secure the necessary capital to fund its operations. Financial Analysis: A Precarious Path Forward A thorough review of Palisade Bio's SEC filings paints a picture of a company with a critical need for capital. As of the latest quarterly report for the period ending March 31, 2025, the company's financial position is characterized by: * Limited Cash Runway: While specific current cash on hand is not publicly available, analysis of past burn rates and recent financing activities suggests a limited operational runway. The company will need to secure additional funding to advance PALI-2108 through further clinical trials. * Recent Financing: In December 2024, Palisade Bio closed a $5 million underwritten public offering. Such financing activities, while necessary for survival, can lead to shareholder dilution. * Negative Earnings: As a clinical-stage company with no commercial products, Palisade Bio has a history of negative earnings per share (EPS). This is typical for the sector but underscores the long road to potential profitability. Investors should closely monitor the company's cash burn rate and any future financing announcements, as these will be critical determinants of its viability. Clinical Pipeline: PALI-2108 Shows Early Promise Palisade Bio's clinical pipeline is currently centered on a single asset, PALI-2108. * PALI-2108 for Ulcerative Colitis: This oral PDE4 inhibitor is designed as a prodrug, meaning it becomes active only when it reaches the colon. This targeted approach aims to minimize the systemic side effects, such as nausea and vomiting, that have plagued other oral PDE4 inhibitors. * Positive Phase 1a Results: In May 2025, the company announced positive topline results from its Phase 1a single-ascending dose trial of PALI-2108 in healthy volunteers. The drug was reported to be well-tolerated and demonstrated the intended colon-specific activity. * Phase 1b Underway: Following the successful Phase 1a, Palisade Bio has initiated a Phase 1b multiple-ascending dose study in patients with ulcerative colitis. The results from this trial will be a significant catalyst for the company. * Precision Medicine Approach: The company has entered into a collaboration with Strand Life Sciences to leverage bioinformatics and identify biomarkers that could predict patient response to PALI-2108. This precision medicine strategy could enhance the probability of success in later-stage trials. The early clinical data for PALI-2108 is encouraging, but the drug is still in the very early stages of development. The path to regulatory approval is long and fraught with potential setbacks. Management and Corporate Governance: Experienced Leadership at the Helm Palisade Bio is led by a management team with experience in both the scientific and financial aspects of the biopharmaceutical industry. * JD Finley, Chief Executive Officer: Mr. Finley has a background in finance and has been instrumental in securing capital for the company. His financial acumen will be crucial as Palisade Bio navigates its current financial challenges. * Mitchell Jones, MD, PhD, Chief Medical Officer: Dr. Jones brings extensive experience in gastroenterology and clinical development. His expertise will be vital in guiding the clinical strategy for PALI-2108. * Recent Board Addition: In July 2025, the company appointed Emil Chuang, MB BS FRACP, to its Board of Directors. Dr. Chuang has a track record of successful clinical development in IBD, further strengthening the company's expertise in its target therapeutic area. The experience of the management team and board provides a degree of confidence in the company's ability to execute its clinical and financial strategies. Competitive Landscape: A Crowded Field with a Niche Opportunity The market for IBD treatments is a multi-billion dollar industry dominated by large pharmaceutical companies with established biologic therapies. However, there is a significant unmet need for safe and effective oral treatments. * Direct Competitors: The oral PDE4 inhibitor space for IBD includes other companies in various stages of clinical development. A key differentiator for Palisade Bio will be to demonstrate a superior safety and efficacy profile for PALI-2108, leveraging its colon-targeted mechanism. * Broader Competition: Beyond other PDE4 inhibitors, PALI-2108 will compete with a wide array of oral and injectable therapies with different mechanisms of action. Palisade Bio's success will depend on its ability to carve out a niche for PALI-2108 by proving a tangible clinical benefit, particularly in terms of safety, over existing and emerging therapies. Conclusion: High-Risk, High-Reward Proposition Investing in Palisade Bio at its current stage is a speculative endeavor with the potential for significant returns, but also the risk of substantial loss. The company's future is almost entirely dependent on the successful clinical development and eventual commercialization of PALI-2108. Key catalysts for investors to watch include: * Results from the ongoing Phase 1b trial of PALI-2108. * Announcements of any new financing activities. * Updates on the collaboration with Strand Life Sciences and the development of a biomarker strategy. * Initiation of a Phase 2 clinical trial for PALI-2108.

christed272

📊 AYTU – Superstock Checklist # Criterion Meets? Comments & Data 1 Price $1–$15 ✅ Yes $2.32 (July 16, 2025) 2 Breakout from strong base ✅ Yes Recent breakout after earnings, strong technical signals 3 Breakout above 30WMA ✅ Yes Price is well above 50- and 200-day MAs ($1.93 / $1.67) 4 Massive weekly volume ✅ Yes Typical: ~200k, recent spikes >1M (Finviz) 5 Steep angle of attack ✅ Yes Up 28% YTD, +34% after news; sharp move visible 6 Clean chart ✅ Yes Few gaps, clear uptrend since base 7 Prior momentum ✅ Yes Multi-month uptrend after strategic restructuring 8 Acts like a superstock (‘magic line’) ✅ Yes Outperforms other small-cap biotechs, clear breakout 9 EPS positive ✅ Yes Q3 FY25: $0.21; Q2 FY25: $0.13 10 Earnings sustainable ✅ Yes Revenue growth 2024–2025; recurring pharma income 11 P/E ≤ 10 ✅ Yes No standard P/E, forward P/S ~0.99; EV/EBITDA ~4 12 Sequential improvement ✅ Yes Q-on-Q improvement visible 13 Easy YoY comparison ✅ Yes +32% sales, +65% EBITDA YoY 14 High operating leverage ✅ Yes High margins, EBITDA >$600k on $18M sales (~22%) and growing 15 Increasing backlog ✅ Yes New contracts (EXXUA commercialization) show pipeline is growing 16 Insider buying? ✅ Yes CEO bought 15k shares @ $1.30; other officers also bought 17 Low float & market cap ✅ Yes ~$20M market cap, float ~6.7M shares 18 IT factor ✅ Yes Focus on ADHD/depression meds (EXXUA, Adzenys, etc.) 19 Conservative management ✅ Yes Strong cash, low debt/EBITDA ~2.9; refinancing April 2025 20 Simple headlines ✅ Yes “First-in-class antidepressant approved...” etc. 21 No listed options ❌ No Options available (Finviz) 22 Little/no competition ⚠️ Partial Biotech always has competition, but EXXUA is unique in its class 23 Low short interest (<20%) ✅ Yes Short interest very low (<5%) 24 Not highly leveraged ✅ Yes Debt/equity only 0.65 25 Not a commodity play ✅ Yes Pure pharma, no commodities exposure 26 IBD 100 ❌ No Not included 27 No analyst coverage ⚠️ Limited Lake Street covers it, but little mainstream coverage 28 Super traders on board ❌ No No large hedge funds or “supertrader” presence 29 Insider ownership 20–30% ✅ Yes Insiders/founders historically ~20%+ (CEO, CCO, etc.) 30 Long trading history, not recent IPO ✅ Yes Public since ~2015, no SPAC/recent IPO 31 Great ticker ✅ Yes “AYTU” is short, clear, and unique 📈 Score & Evaluation ✅ Fully met: 27 / 31 ⚠️ Partial: 22 (competition), 27 (analyst coverage), 16 (recent insider buys – present but not massive) ❌ Not met: 21 (options), 26 (IBD 100), 28 (supertraders) 🔍 Summary Aytu BioPharma is a very strong Superstock candidate per Jesse Stine’s method: ✔️ Profitable, breakout, high momentum ✔️ Low float, microcap, recurring revenue, strong new product (EXXUA) ✔️ Solid insider discipline, clear headlines, growing backlog ✔️ No commodity risk, low debt, minimal analyst/hype risk Risks: options exist, limited analyst coverage, biotech always has competition and event risk.

uqubar

MP News... [https://www.investors.com/news/mp-materials-stock-soars-pentagon-launches-rare-earths-war-china/?mod=IBD\_FV](https://www.investors.com/news/mp-materials-stock-soars-pentagon-launches-rare-earths-war-china/?mod=IBD_FV)

FitAd9625

ROKU a few years ago. Recommended by IBD. I found all of their advice to be absolutely worthless.

Busy-Block-1603

Did anyone here successfully participate in over subscribed high profile IPOs, what's your experience? As a retail investor do you even have a chance to get 5-10k USD (say with IBKR) if the IPO is hot or does one end up with just a few hundreds (since everything goes to HFs, and other institutional clients)? Thinking to participate at their IPO. I have account with solid European bank as a broker which covers all my needs except US IPOs, but I think even if their IBD participates, they won't route it to retail. Was thinking if it makes sense to open IBKR account but then again if IPO is over subscribed then will have to buy later on T or on T+1 and if it's not over subscribed then probably doesn't matter anyways buying on T+1 at 20-30% premium, which is not a big deal since I hold my positions for years anyways.

Mhipp7

You have to decide what type of investor you want to be. Plenty of good ETF’s but if you want to start in stocks then take a look at IBD app for ideas & articles. William O’Niels books are a good place to start.

Deep_INDA_Money

Nvidia stock is in a 20-week consolidation pattern with a buy point of 153.13, according to IBD MarketSurge charts. 🤔 💭

Which_gods_again

IBD says not even Harry Potter is safe from inflation. https://preview.redd.it/kj5of75odm1f1.jpeg?width=1080&format=pjpg&auto=webp&s=b6f282f97df699ed25aa61a9366cb88970969c8f

LargeSand

In Sweden, medication for any lifetime conditions such as chronic autoimmune disease are free for life. So that includes diabetes, IBD, HIV, etc.

Natural_Barracuda_68

-Compound and Friends with Josh Brown snd Batnick -Best Stocks Now Bill Gunderson daily stock show -IBD after hours recap and highlight 3 stocks from IBD list -CNBC Halftime Report. Good for broad sense of market -Founders -All In. These guys are fool of themselves but some good nuggets are picked up -Macro Voices -Invest Talk -Motley Fool I listen to a bit of different perspectives. I listen and read a lot so I speed up to 1.5 sometimes 1.75. To make consistent money you must always make it a habit to learn and keep up with the daily markets. I don’t believe in being passive and buying an index and letting it sit.

footlong24seven

I'm so upset with myself for not pulling the trigger on DAVE. Was looking at calls for 120 right before earnings. Would have been 10x+. Those don't come often and I was right there. But I had an awful week and decided not to risk shooting myself in the foot again. I'll give props to IBD for putting this one on my radar. ROOT has similar behavior, as well as MRX.

Cute-War-4115

Here’s IBD telling you you’re wrong: https://www.investors.com/news/trump-tariffs-trade-war-us-ports-empty/

1970s_MonkeyKing

I dunno what to think about it. Meta almost doubles its spending over last year. The IBD Composite Rating lists six crypto ventures as part of their 'Top 21' IPOs to invest in. And some investment houses are saying that a $300 Tesla is still viable. Did the grownups leave the room and their five year olds get control of their laptops?

noplanman_srslynone

>Apple Tariff Exemption Odds Increasing As China Levies Kick In -- IBD Hope and Cope I think

fallingdowndizzyvr

> This strategy you linked also seems pretty IBD specific, not particularly common strategy on /r/investing. Right in this very thread it was talked about. That was what was meant by "We haven’t hit bottom yet." https://www.reddit.com/r/investing/comments/1jrdl09/my_portfolio_has_dropped_from_61k_to_38k_in_the/mlds7b6/ > But for my part, my investing strategy is going to continue to be investing a % of my paycheck every month consistently. Which you are welcomed to do. Many people choose to do passive investment. I on the other hand will continue to be strategic and tactical.

Shanman150

> If it's all besides the point, then why did you post a link where that was the point? I literally said what the point of it was, it was to show that dollar cost averaging would lead to a total recovery of your funds, even if you were invested prior to the peak, before the market as a whole returned to pre-1929 levels. Unfortunately that website only shows S&P500 returns, but if you want to specifically look at the Dow Jones (which did take longer to recover), we can do the math there. There wasn't a quick way to do this, so I had to break it out in excel. |Year|Dow Jones|Lump|DCA| --:|--:|--:|--:| |1/1/1925|121.55|$100,000.00|$833.33| |1/1/1926|156.1|$128,424.52|$12,568.88| |1/1/1927|154.65|$127,231.59|$22,597.55| |1/1/1928|198.95|$163,677.50|$40,242.37| |1/1/1929|307.25|$252,776.64|$75,440.11| |1/1/1930|255.65|$210,324.97|$71,363.34| |1/1/1931|167.25|$137,597.70|$54,242.57| |1/1/1932|78.55|$64,623.61|$31,942.29| |1/1/1933|61.85|$50,884.41|$35,272.07| |1/1/1934|102.85|$84,615.38|$71,049.84| |1/1/1935|103.2|$84,903.33|$81,860.28| |1/1/1936|146.3|$120,361.99|$128,065.71| |1/1/1937|182.3|$149,979.43|$170,716.25| |1/1/1938|127.25|$104,689.43|$127,262.01| |1/1/1939|145.65|$119,827.23|$156,708.89| |1/1/1940|148.75|$122,377.62|$170,564.99| |1/1/1941|128.85|$106,005.76|$157,468.56| |1/1/1942|111.55|$91,772.93|$145,618.85| |1/1/1943|122.42|$100,715.75|$171,170.32| |1/1/1944|137.28|$112,941.18|$202,036.75| |1/1/1945|153.6|$126,367.75|$236,698.08| |1/1/1946|198.12|$162,994.65|$316,795.27| |1/1/1947|176.2|$144,960.92|$291,131.77| |1/1/1948|176.11|$144,886.88|$300,908.68| |1/1/1949|178.28|$146,672.15|$314,502.65| |1/1/1950|199.79|$164,368.57|$363,529.45| |1/1/1951|244.45|$201,110.65|$455,931.34| |1/1/1952|271.71|$223,537.64|$517,239.88| |1/1/1953|288.44|$237,301.52|$559,696.14| |1/1/1954|286.64|$235,820.65|$566,603.55| |1/1/1955|398.43|$327,791.03|$799,295.37| |1/1/1956|474.75|$390,580.01|$963,010.52| Here, the difference is actually even more clear. You'd have all of your initial investment back before you finished investing that first $100,000 (DCA'd across 10 years). And you'd have done it through the worst of the depression, catching the whole knife on the way down, with 40% of your initial investment already in before the market collapsed. And again, we're not comparing directly to lump sum investing (though here DCA beats that), it's just a comparable benchmark. By all means, you're welcome to take some technical analysis approach to investing if you like - I tend to think TA works until it doesn't. This strategy you linked also seems pretty IBD specific, not particularly common strategy on /r/investing. Again, that's just based on my experience here - this is the first time I've seen someone link to that strategy in the last 5 years I've been subscribed here. Maybe you could backtest that strategy specifically on the Great Depression and show how much better it does. But for my part, my investing strategy is going to continue to be investing a % of my paycheck every month consistently.

rocketsplayer

Yes I am sure you know more about market then William O’Neill and the thousands who successfully use IBD strategy

1ATRdollar

IBD

rocketsplayer

Actually been managing money and timing since opened in 1997 following IBD principles and am not delusional and sleep fine

BellyFullOfMochi

Even IBD is negative about the stock market right now lol

Future_Class3022

Warren Buffett's Berkshire Hathaway, IBD Stock Of The Day, Leads S&P 500 Out Of Correction https://www.investors.com/research/ibd-stock-of-the-day/warren-buffett-berkshire-hathaway-brkb-leads-sp-500-correction/

BluesFlute

Money is not for play. I say this, not to be a PIA, but to emphasize that if money is important to you, getting one’s head straight about it is essential. Read a few books on stock investing and think about it awhile. Are you fundamental analysis or technical analysis oriented, or maybe both? Know that quality information is rarely free, except on Reddit. Ha! Get a subscription to IBD, or StockCharts or Barrons. Sample them in your public library. That said, market sell offs , “corrections” are common and pundits always have explanations afterwards. Buy now? Probably not. There’s more work to be done to the downside. There’s a lot of political stink in the air. Jaime Dimon is not smiling. Sell offs and subsequent recovery is not usually V shaped. It takes time. Money market account for now while you plan the next steps. FOMO is real. Investing emotionally is a good way to lose. In that case, consider going to a casino, it’s more fun.

Jumpinmycar

I heard from IBD that total outflows outpacing inflows over several trading days usually flags a longer term bear market Hence me asking

Laureles2

No a recession is not guaranteed, nor is it even likely according to the top economists and investment advisors. I listen to Bloomberg, Reuters, and MSN daily ... also read a lot of IBD ... and no one is saying that.

stevenryl866

Get ONVO while it’s cheap! While the exact milestone payments for Organovo’s FXR314 acquisition by Eli Lilly have not been disclosed, we can estimate a range based on industry norms for similar deals. Expected Milestone Payment Range 1. Upfront Payment • Typically, early-stage biotech deals (Phase 1/2) see upfront payments between $50M–$300M. • If FXR314 shows strong Phase 2 potential, the upfront payment could be $100M–$250M. 2. Regulatory Milestones (Phase 2b, Phase 3, FDA Approval) • Phase 2b completion: $50M–$150M • Phase 3 initiation: $100M–$250M • FDA approval: $200M–$500M 3. Commercial Milestones (Sales-Based Payments) • First commercial sale: $50M–$150M • Sales milestones (e.g., hitting $500M or $1B in revenue): $200M–$500M Total Potential Deal Value • If FXR314 progresses successfully, the total deal value (upfront + milestones) could be in the range of $500M–$2B, similar to other IBD drug acquisitions (e.g., Eli Lilly’s $3.2B Morphic deal). These numbers are estimates based on comparable deals, and the actual structure will depend on FXR314’s competitive positioning and future performance.

ScienceFantastic4041

Honestly the IBD job will be probably be more than 60 hours a week, very late nights etc. Good grad experience though.

cjp_1989

Holding hope for SOBR for one more day. STTK is also supposed to be presenting Preclinical data on their IBD drug today.

dimethylhyperspace

That would be amazing, and horribly managed..prob worse than Cathy woods 😂 But I would buy it. I mean, motley fool, IBD and all those jokers have their own ETFs..of course, the WSB ETF would have to be double leveraged. At least

IosifVissarionovichD

Any votes here for IBD?

NickFury6666

ROKU. Based on advice from Investors Business Daily. There some other dogs from IBD, but ROKU was the worst. Whstever IBD recommends, do the opposite.

Least_Inspector_450

10 years in IBD / Corp Strat / VC would suggest so. But what do I know? And how’s that PLTR short going, chief?

IRUL-UBLOW-7128

What is the William O Neil rule? According to IBD founder William O'Neil's rule in "How to Make Money in Stocks," **you should sell a stock when you are down 7% or 8% from your purchase price**, no exceptions. Having a rule in place ahead of time can help prevent an emotional decision to hang on too long. It should be: Sell now, ask questions later. Yes, there is more to it than that, BUT I have always followed his advice. YRMV.

uraz5432

There are some automatic ways like for example in thinkorswim there’s price channel indicator. However if you want to learn more, you can catch several videos on YouTube from IBD, on twitter I follow Jake Wujatsky, Enrich Trades and several other accounts that post charts for free on well known stocks for breakout entries

Historical_Stage2622

[Q4 Earnings Estimates Look Quite Strong For These IBD 50 Names, Including Palantir Stock | Investor's Business Daily](https://www.investors.com/research/earnings-preview/palantir-stock-ai-stock-earnings-power/?src=A00650&refcode=rbnhdfeed)

maitez84

- Traderlion - Richard Moglen - IBD

httmper

Yes I know. I wanted Barron’s and IBD as well which was 1.75.

theoptiontechnician

I believe IBD gives a lot of option suggestions for free if you get the app. I'm not a believer that we need to look at over 1000 etf/stocks a week to fine the best one. Good luck.

id_never_eat_here

I was in the same boat. Read: *How to Make Money in Stocks* by William J. O'neil. Then use [investors.com](http://investors.com) to find and evaluate companies you are interested in. I started trading buying stocks and built up my account. Then learned options and futures, I did extremely well for about 6 months... Then I blew up my account. Continued to trade options and futures for another 2 years jumping from strategy to strategy. I would make a little progress, then take losses and be right back where I started. I have been applying what I learned from that book, and using IBD for research. I am back to buying shares and very rarely trade options. When I do use options I have a very different perspective. I have been taking more of a swing trade approach.

waitingattheairport

WSJ MarketWatch IBD. Big sale

Beginning-Cry7722

Is anyone subscribed to WSJ+? WSJ+ includes WSJ and IBD along with Barrons and Marketwatch. I’m looking to learn about individual stocks and investing and be more updated. I’m mainly interested in Barrons. WSJ+ is available at $1.75/week while Barrons + MW is at $1.25.

KRowland08

My Podcast Library (all on Apple Podcasts) Some are just market updates and some are analysis and some interviews. **Daily Morning Briefings -** Opening Bid, Yahoo Finance Wall Street Breakfast, Seeking Alpha Morning Wire, Daily Wire What's News, WSJ Morning Brew Daily **Afternoon After Market Wraps --** Stock Market Today, Investors Business Daily Schwab Market Update, Schwab **Weekly In-Depth Coverage and Info --** On Investing, Schwab We Study Billionaires, Investor Podcast Network Swing Trading The Stock Market The Journal, WSJ Patrick Boyle on Finance Investing Insights, MorningStar Barron's Streetwise Investing with IBD, Investors Business Daily Investing Experts, Seeking Alpha

OpportunityGold4054

Our biggest mistake was relying on financial planners (we had three in succession as we moved around) when we could have been making our own investments in stocks. Once we learned the steps involved in sound growth investing our returns far, far, outpaced anything our advisors did. (They were always shocked at the returns I was getting on my part of the portfolio). And that wasn’t even considering the $20,000/year in their fees and charges for funds we had to pay. You can develop your own style and methods, but I used IBD, TMFool, and the Fidelity research analysts’ pages to learn. Easy and fun! Try it with a small segment of your savings snd then enlarge your amount as u gain confidence. Good luck!

thekinggrass

Tipping is definitely on traders minds. Nasdaq is extended but it just bounced off the 50 last week. Same with SP500. There’s been rotation into small caps and crypto stocks which are moving. I will say IBD did a “how to spot a top” podcast a couple weeks ago and that’s always telling. It’s on traders minds, I expect some profit taking and tax loss harvesting through the end of the year. When your favorite (real) traders start to call tops then it’s usually time to exit. That hasn’t happened left and there are a ton of bullish charts out there.

TravellingBeard

Yeah, i gave up on Motley Fool. I have toyed with Investor's Business Daily before. I may resubscribe to them, but curious if anyone here subscribes to IBD currently and their experience? I know it's more growth oriented while MF is more value focused.

Plantastic24

I checked it using IBD's tool: [https://research.investors.com/stock-checkup/nasdaq-celsius-holdings-celh.aspx](https://research.investors.com/stock-checkup/nasdaq-celsius-holdings-celh.aspx) 7 of 100, yikes Don't touch!

Beginning-Cry7722

# WSJ+ Subscription for $1.75/week.. Worth it for a "newbie" to learn/invest?  I have been a "lazy investor". I read news and buy some big tech (Apple, AMZN..) type stocks and tech ETFs (tech because I understand tech) and let them grow when I have funds available. I usually search for a company stock, browse the latest happenings and decide on buying these stocks. Free news would be great. But I saw this offer for WSJ+ which includes WSJ, MarketWatch, Barrons and IBD. This is within my budget. I know I wont read all 4 every single day. Should i just pick one and subscribe? I want to understand these businesses more because I'm looking to invest more actively and with more knowledge. I'd like to understand what their primary investments and business strategies are. A lot of Barrons and Bloomberg is blocked by paywall. I liked some of the Bloomberg podcasts because they were so concise. But the site seems blocked by paywall. Should I consider any other resources? Finviz UI seems chaotic.

_Rexfest_

IBD breakthrough. America is infested with it, and so am I. This one is for my condition!

BIGDADDYHANIN

I had to breakdown and get a dollar a week WSJ, Barrons, IBD sub

FivePoppedCollarCool

There's a lot of misinformation in this thread 1) All groups use any/all publicly available information 2) The Equity Research (ER) group does independent research using publicly available information, talking to their contacts in industry, talking to the companies, etc. to write research reports and make recommendations. They are allowed to talk to Sales & Trading (S&T) as well to see what their thoughts are. However, ER does not make decisions based on what S&T is trying to do or what they're holding in their book. ER wants to make decisions based on real research and what they think the market will do in order to make a name for themselves. They consider themselves entrepreneurs who are creating a brand. Take Jeff Currie from Goldman as an example. Jeff's research was great and his thoughts were intellectually stimulating. So if Goldman trading was long Exxon and Jeff thinks oil is going to $2, he's not going to ruin his reputation by selling the traders book. 3) In the U.S., ER gets paid when investment managers do trades through the S&T team. So a hedge fund will get a research report, call the analyst for clarification or to just chat about the industry. When they put in an order to buy/sell the stock the analyst covers, the trader gets the flow and the ER analyst gets the credit and everything is good. Europe is different - I think you have to pay for the research directly now? I don't know, I left the industry before MiFID II. 4) Investment Banking (IBD) is the group I was in. They deal with non-public information and they don't interact with ER or S&T until there's an IPO or something where you need to bring the ER team and/or S&T team over the wall. We basically just didn't speak to anyone else unless compliance specifically told us to do so and even then we had compliance on all calls/emails/etc. between us and the other groups. Throughout your day-to-day, compliance is watching all emails, all calls, messages, etc. They take this shit very seriously. The "Chinese wall" is very very real and no one fucks with it. Theoretically speaking with what is considered legal or not, ER should NOT tell anyone what their research report will say, if they're upgrading/downgrading/etc. Because that is material non-public information. So in this NVDA and BAML case, S&T and IBD had no idea what ER was going to do. However, if you really want to toe the line opf legal, other than the contents of an upcoming research report, ER/S&T can tell the IBD guys anything they want because the information they have should be public. However, since it's hard to make sure the information flow is only one way, and to avoid slips, banks simply have a blanket "no communication between IBD & ER/S&T" rule Hope this helps. Happy to answer more questions

Rav_3d

I agree, blindly buying the IBD 50 is not a good strategy. I do find their stock ratings useful as part of my analysis for picking stocks. I especially use the RS rating during corrections and pullbacks to identify stocks holding up better than most.

chappyandmaya

I find IBD next to useless myself. They offer an ETF flavored to their Nifty Fifty picks and it’s hot garbage. Hopefully you have better luck!

apiercex1

Investors Business Daily is a company/database created by William O'Neil to provide individual investors with information so they can do their own analyses in one place and so they can make their own decisions without relying on others. Highly highly recommend reading How to Make Money in Stocks by O'Neil and Profiting in Bull and Bear Markets by Weinstein. Take what you learn from these 2 books together, and use the information from IBD, and I'm confident people won't need to rely on others for stock investments. They will answer your questions on when to buy, hold, sell. If you read them you won't need this sub and will be ahead of 95% of other people IMO. Note: you can get some info for free but the paid subscription is worth it imo. Especially if you do your homework. Read those 2 books first as your homework, starting with O'Neil. Then consider the IBD subscription. This changed me for the better. Hope this helps.

Onedown-6togo

It just got extended from its $19.80 buy point. As an IBD stock, I’d hold on for now. What was your buy in price?

bmeisler

Srsly, the IBD method is to pick 10 stocks or so, based on their recommendations and your own research, and sell when you’re either up 20% or down 6-8% (more like 40-50% and 15-20% with options). Works well in a bull market! As long as you don’t get hit by the once rare now seemingly commonplace overnight 20% drops.

Mariposaland

Momentum, new highs, daily volume, using IBD relative strength model, plus CAN SLIM. I used to have all the documentation but I am entirely in real estate. Google it.

NYIslanders22

IBD is a good resource for info on stocks / companies. No I don’t work for them but I subscribe.

investinreddit-

You're brave and I'm glad you are confident. I don't buy the dips but understand the growth can be there.. The reality is the companies.that have 10x have jumped.up.100% before they jump more (FAANG) so I don't feel worried buying when some.stocks are at highs or have great price action and relative strength. But then again I use the William.O.Neil CAN model.or.whatever it's called. Investor Business daily is the closest thing to it with marketsurge but be careful with the IBD leaderboard because you might buy in too late exactly your point. Best wishes and best of heath to you my brother.

DepartureOk8774

I'm a TTG member, "Lifetime" and "AI Lifetime", there is tremendous value in being in a trading community. Michael gives continuous or daily updates, as well before the open. Find me in the Charting section everyday "EricWebb", I'll be discussing set ups with the moderator and a few others where we text back and forth and show screens. I use IBD and William O'Neils principals, have been for 5 years, its all good and we mill move on when a trade or set up doesn't work.

StockerDocker

What is IBD

timestreamdefender

Software after hardware seems to have entered the chat this past week at IBD. I will be observing 👌

katiajojo

theyre all from IT/ops/infrastructure backoffice roles/marcus buildout/apple card integration. they served their purpose and their salary was paid via ERC. now that the expense is real, their time at GS is over. if this was S&T/IBD layoffs the market wouldve closed -1% today.

Captain-Popcorn

FFTY - Innovator IBD 50 ETF

asfg812

They are now profitable (qtr 2) and have increasing scrips. IBD (Investors Business Daily) chose it as their stock of the day Friday ( 8/16), and ranking it in their IBD 50 which gets it bought by their ETFs. Major buying from large institutions with high volume, and 30% short interest with 14 days to cover. CEOs long-term focus has been on fair value buyout at more than $ 60+. Market niche is projected to $20 B. TG is grabbing market share focusing on Academic Medical Centers and major prescribers. Various advantages over Ocrevus, recent contract with Veterans Administration, high acceptance with MS Knowledge and Opinion Leaders. It's been developing for a long time, but is hitting its stride. Either expecting buyout after it gets to $40+, or riding the profits and growth independently. CEO Mike Weiss won't let it go cheap. He recently announced a stock buyback up to $100 million to force the shorts out.

RetiredSailDoc

Get the IBD app and put stock symbol into search and will give you stats and technical analysis.

uraz5432

Lots of material available on YouTube- trader lion, IBD review videos, stock charts tv videos, and trader talks from Schwab with live webinar classes on all topics from beginner to advanced including options. Lots of paid subscription for day trading as well: ripster, saty, etc you can find more on twitter For serious investment look up seeking alpha for deep dive and analysis.

Previous_Golf_5959

IBD suggested selling when you're down 8% to avoid catastrophic losses. I've abided by that for 40 years and adhering to that rule has not failed me. Remember to not cultivate your weeds while picking your flowers.

greytoc

>... read the daily paper. Usually WSJ or more recently IBD. That comment gave me a smile - I appreciate that you actually remember that IBD used to be a daily print paper. And that you still consider it recent.